DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,063 | -30.1% | 100 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $2,951 | +28.1% | 100 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $2,304 | -17.2% | 100 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $2,781 | -7.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,000 | -25.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $4,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 5,960,732 | $122,969,901 | 14.32% |
| ARCH Venture Management, LLC | 693,749 | $14,312,042 | 9.30% |
| Flagship Pioneering Inc. | 2,619,968 | $54,049,940 | 3.92% |
| Casdin Capital, LLC | 1,300,000 | $26,819,000 | 2.97% |
| Yiheng Capital Management, L.P. | 1,150,684 | $23,738,611 | 1.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 154,000 | $3,172,400 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 254,941 | $5,259,433 | 1.02% |
| Temasek Holdings (Private) Ltd | 6,895,992 | $142,264,315 | 0.85% |
| Clarius Group, LLC | 378,262 | $7,803,545 | 0.74% |
| Artal Group S.A. | 802,899 | $16,564 | 0.71% |